Clinical use of lithium salts: guide for users and prescribers

for the International Group for Studies of Lithium (IGSLi)

doi:10.1186/s40345-019-0151-2

Clinical use of lithium salts: guide for users and prescribers

for the International Group for Studies of Lithium (IGSLi)

Medicine

Research output: Contribution to journal › Review article › peer-review

143 Citations (Scopus)

Abstract

Background: Lithium has been used clinically for 70 years, mainly to treat bipolar disorder. Competing treatments and exaggerated impressions about complexity and risks of lithium treatment have led to its declining use in some countries, encouraging this update about its safe clinical use. We conducted a nonsystematic review of recent research reports and developed consensus among international experts on the use of lithium to treat major mood disorders, aiming for a simple but authoritative guide for patients and prescribers. Main text: We summarized recommendations concerning safe clinical use of lithium salts to treat major mood disorders, including indications, dosing, clinical monitoring, adverse effects and use in specific circumstances including during pregnancy and for the elderly. Conclusions: Lithium continues as the standard and most extensively evaluated treatment for bipolar disorder, especially for long-term prophylaxis.

Original language	English
Article number	16
Journal	International Journal of Bipolar Disorders
Volume	7
Issue number	1
DOIs	https://doi.org/10.1186/s40345-019-0151-2
Publication status	Published - Dec 1 2019

Bibliographical note

Funding Information:
Supported by grants from the Bruce J Anderson Foundation and the McLean Private Donors Psychiatric Research Fund (to RJB). VB has received grants by the Blavatnik Women’s Health institute. RWL has received research grants from Glaxo Smith Kline, honoraria for lecturing from Pfizer, Glaxo Smith Kline, Eli Lilly, Astra-Zeneca, Bristol-Myers Squibb, Janssen Cilag, Lundbeck, Otsuka, Servier and honoraria from advisory board activity from Glaxo Smith Kline, Eli Lilly, Astra-Zeneca, Bristol-Myers Squibb, Janssen Cilag and Sunovion. LT has received honoraria from advisory board for Angelini. No other authors or immediate family members have financial relationships with commercial entities that might appear to represent potential conflicts of interest with the information presented. The remaining authors declare that they have no competing interests.

Publisher Copyright:
© 2019, The Author(s).

ASJC Scopus Subject Areas

Psychiatry and Mental health
Biological Psychiatry

PubMed: MeSH publication types

Journal Article
Review

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1186/s40345-019-0151-2

Cite this

@article{981bf17b5ab242b8a6c87ed42cc37af7,

title = "Clinical use of lithium salts: guide for users and prescribers",

abstract = "Background: Lithium has been used clinically for 70 years, mainly to treat bipolar disorder. Competing treatments and exaggerated impressions about complexity and risks of lithium treatment have led to its declining use in some countries, encouraging this update about its safe clinical use. We conducted a nonsystematic review of recent research reports and developed consensus among international experts on the use of lithium to treat major mood disorders, aiming for a simple but authoritative guide for patients and prescribers. Main text: We summarized recommendations concerning safe clinical use of lithium salts to treat major mood disorders, including indications, dosing, clinical monitoring, adverse effects and use in specific circumstances including during pregnancy and for the elderly. Conclusions: Lithium continues as the standard and most extensively evaluated treatment for bipolar disorder, especially for long-term prophylaxis.",

author = "{for the International Group for Studies of Lithium (IGSLi)} and Leonardo Tondo and Martin Alda and Michael Bauer and Veerle Bergink and Paul Grof and Tomas Hajek and Ute Lewitka and Licht, {Rasmus W.} and Mirko Manchia and Bruno M{\"u}ller-Oerlinghausen and Nielsen, {Ren{\'e} E.} and Marylou Selo and Christian Simhandl and Baldessarini, {Ross J.}",

note = "Funding Information: Supported by grants from the Bruce J Anderson Foundation and the McLean Private Donors Psychiatric Research Fund (to RJB). VB has received grants by the Blavatnik Women{\textquoteright}s Health institute. RWL has received research grants from Glaxo Smith Kline, honoraria for lecturing from Pfizer, Glaxo Smith Kline, Eli Lilly, Astra-Zeneca, Bristol-Myers Squibb, Janssen Cilag, Lundbeck, Otsuka, Servier and honoraria from advisory board activity from Glaxo Smith Kline, Eli Lilly, Astra-Zeneca, Bristol-Myers Squibb, Janssen Cilag and Sunovion. LT has received honoraria from advisory board for Angelini. No other authors or immediate family members have financial relationships with commercial entities that might appear to represent potential conflicts of interest with the information presented. The remaining authors declare that they have no competing interests. Publisher Copyright: {\textcopyright} 2019, The Author(s).",

year = "2019",

month = dec,

day = "1",

doi = "10.1186/s40345-019-0151-2",

language = "English",

volume = "7",

journal = "International Journal of Bipolar Disorders",

issn = "2194-7511",

publisher = "Springer Open",

number = "1",

}

TY - JOUR

T1 - Clinical use of lithium salts

T2 - guide for users and prescribers

AU - for the International Group for Studies of Lithium (IGSLi)

AU - Tondo, Leonardo

AU - Alda, Martin

AU - Bauer, Michael

AU - Bergink, Veerle

AU - Grof, Paul

AU - Hajek, Tomas

AU - Lewitka, Ute

AU - Licht, Rasmus W.

AU - Manchia, Mirko

AU - Müller-Oerlinghausen, Bruno

AU - Nielsen, René E.

AU - Selo, Marylou

AU - Simhandl, Christian

AU - Baldessarini, Ross J.

N1 - Funding Information: Supported by grants from the Bruce J Anderson Foundation and the McLean Private Donors Psychiatric Research Fund (to RJB). VB has received grants by the Blavatnik Women’s Health institute. RWL has received research grants from Glaxo Smith Kline, honoraria for lecturing from Pfizer, Glaxo Smith Kline, Eli Lilly, Astra-Zeneca, Bristol-Myers Squibb, Janssen Cilag, Lundbeck, Otsuka, Servier and honoraria from advisory board activity from Glaxo Smith Kline, Eli Lilly, Astra-Zeneca, Bristol-Myers Squibb, Janssen Cilag and Sunovion. LT has received honoraria from advisory board for Angelini. No other authors or immediate family members have financial relationships with commercial entities that might appear to represent potential conflicts of interest with the information presented. The remaining authors declare that they have no competing interests. Publisher Copyright: © 2019, The Author(s).

PY - 2019/12/1

Y1 - 2019/12/1

N2 - Background: Lithium has been used clinically for 70 years, mainly to treat bipolar disorder. Competing treatments and exaggerated impressions about complexity and risks of lithium treatment have led to its declining use in some countries, encouraging this update about its safe clinical use. We conducted a nonsystematic review of recent research reports and developed consensus among international experts on the use of lithium to treat major mood disorders, aiming for a simple but authoritative guide for patients and prescribers. Main text: We summarized recommendations concerning safe clinical use of lithium salts to treat major mood disorders, including indications, dosing, clinical monitoring, adverse effects and use in specific circumstances including during pregnancy and for the elderly. Conclusions: Lithium continues as the standard and most extensively evaluated treatment for bipolar disorder, especially for long-term prophylaxis.

AB - Background: Lithium has been used clinically for 70 years, mainly to treat bipolar disorder. Competing treatments and exaggerated impressions about complexity and risks of lithium treatment have led to its declining use in some countries, encouraging this update about its safe clinical use. We conducted a nonsystematic review of recent research reports and developed consensus among international experts on the use of lithium to treat major mood disorders, aiming for a simple but authoritative guide for patients and prescribers. Main text: We summarized recommendations concerning safe clinical use of lithium salts to treat major mood disorders, including indications, dosing, clinical monitoring, adverse effects and use in specific circumstances including during pregnancy and for the elderly. Conclusions: Lithium continues as the standard and most extensively evaluated treatment for bipolar disorder, especially for long-term prophylaxis.

UR - http://www.scopus.com/inward/record.url?scp=85069477845&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069477845&partnerID=8YFLogxK

U2 - 10.1186/s40345-019-0151-2

DO - 10.1186/s40345-019-0151-2

M3 - Review article

C2 - 31328245

AN - SCOPUS:85069477845

SN - 2194-7511

VL - 7

JO - International Journal of Bipolar Disorders

JF - International Journal of Bipolar Disorders

IS - 1

M1 - 16

ER -

Clinical use of lithium salts: guide for users and prescribers

Abstract

Bibliographical note

ASJC Scopus Subject Areas

PubMed: MeSH publication types

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this